Table 2.

Clinical studies of virus-specific T cells in solid organ transplantation

Cell TherapyIndication N Date StudySolid organ transplantVirus-Specific T Cell DonorActivationDoseGraft Versus Host DiseaseAcute RejectionAdverse EventsDisease-related Outcome
Autologous polyclonal EBV-specific Cytotoxic T cellsEBV+ PTLD11999LungAutologousEBV infected lymphoblastoid cell lines35 × 106 T cells×2 + 60×106 T cells×200Death (pulmonary vein invasion with necrosis and hemorrhage)PTLD near resolution
Allogeneic polyclonal EBV- specific cytotoxic T cellsEBV+ PTLD52002Liver (4), kidney (1) small bowel (3)Frozen bank of CTLs derived from healthy blood donorsEBV infected lymphoblastoid cell lines106/kg x one to six times0003/5 complete remission 2/5 no response
Autologous CMV-specific CD4+ and CD8+ cellsCMV12009LungAutologousOverlapping IE‐1/pp65 peptide pools107 T cells/m2 x 201Death (rejection)CMV resolution
Autologous CMV-specific CD4+ and CD8+ cellsCMV12015LungAutologousAutologous PBMC coated with HLA class I restricted CMV peptide epitopesFour infusions (total of 12 × 107 cells)000Persistent negative CMV PCR
Allogeneic Polyclonal CMV- specific CD4+ and CD8+ cellsCMV12015Kidney3/6 HLA matched third-party donorOverlapping peptides covering pp651.6 × 107 T cells/m2 00Mild fever post VST infusionAt 1 yr CMV viral load declined from 5.5 M to 73 copies/ml
Allogenic BK- specific VSTBKV32017Kidney (1) kidney + heart (1) heart (1)Adult volunteersIFN-γ production in response to repeat stimulation with BKV pepmixes5 × 107T cells/m2 000BKV cleared (1) BK partial response or reduced (2)
  • EBV, Epstein-Barr virus; PTLD, post-transplant lymphoproliferative disorder; CTL, cytotoxic T lymphocytes; CMV, cytomegalovirus; BKV, BK virus.